Tech Company Financing Transactions

Kaleido Biosciences Funding Round

Abu Dhabi Investment Authority, Fidelity Management & Research Company and Flagship Pioneering invested in a $101 million Series C capital raise for Kaleido Biosciences. The round was announced on 6/26/2018.

Transaction Overview

Announced On
6/26/2018
Transaction Type
Venture Equity
Amount
$101,000,000
Round
Series C
Investors

Abu Dhabi Investment Authority

Fidelity Management & Research Company

Flagship Pioneering (Noubar Afeyan)

Invus

Rock Springs Capital

Proceeds Purpose
Kaleido plans to use the proceeds from this financing to advance its pipeline, including conducting multiple clinical studies across several therapeutic areas, and to expand its platform.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
65 Hayden Ave.
Lexington, MA 02421
USA
Email Address
Overview
Kaleido is dedicated to leading a revolution in health. It all starts with the microbiome. In the last ten years, science has revealed the microbiome to be one of the most diverse, powerful organs in the body. At Kaleido, we are pioneering new ways to unlock its power to enable the body to treat disease and heal itself.
Profile
Kaleido Biosciences LinkedIn Company Profile
Social Media
Kaleido Biosciences Company Twitter Account
Company News
Kaleido Biosciences News
Facebook
Kaleido Biosciences on Facebook
YouTube
Kaleido Biosciences on YouTube

Management Team

Title
Name
Email & Social
Chairman
Michael Bonney
  Michael Bonney LinkedIn Profile  Michael Bonney Twitter Account  Michael Bonney News  Michael Bonney on Facebook
Chief Executive Officer
Alison Lawton
  Alison Lawton LinkedIn Profile  Alison Lawton Twitter Account  Alison Lawton News  Alison Lawton on Facebook
Chief Financial Officer
William Duke
  William Duke LinkedIn Profile  William Duke Twitter Account  William Duke News  William Duke on Facebook
Chief Medical Officer
Katharine Knobil
  Katharine Knobil LinkedIn Profile  Katharine Knobil Twitter Account  Katharine Knobil News  Katharine Knobil on Facebook
Chief Scientific Officer
Johan van Hylckama Vlieg
  Johan van Hylckama Vlieg LinkedIn Profile  Johan van Hylckama Vlieg Twitter Account  Johan van Hylckama Vlieg News  Johan van Hylckama Vlieg on Facebook
Co-Founder
Geoffrey von Maltzahn
  Geoffrey von Maltzahn LinkedIn Profile  Geoffrey von Maltzahn Twitter Account  Geoffrey von Maltzahn News  Geoffrey von Maltzahn on Facebook
VP - Bus. Development
Clare Fisher
  Clare Fisher LinkedIn Profile  Clare Fisher Twitter Account  Clare Fisher News  Clare Fisher on Facebook
VP - General Counsel
Jerald Korn
  Jerald Korn LinkedIn Profile  Jerald Korn Twitter Account  Jerald Korn News  Jerald Korn on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/26/2018: PolicyBazaar venture capital transaction
Next: 6/26/2018: MeetMindful venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary